Nasdaq · CIK 0001740279
INAB IN8BIO, INC.
Insider trading from SEC Form 4. Last filing May 12, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
13
with a Form 4 at this company
Signals
Open-market buys and sells at IN8BIO, INC., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 74 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 8, 2025 | Corinne Epperly director | AGrant or award Stock Option (right to buy)derivative | +63,150 | $0.00 | $0 | 63,150 | May 12, 2025 |
| May 8, 2025 | Peter C. Brandt director | AGrant or award Stock Option (right to buy)derivative | +63,150 | $0.00 | $0 | 63,150 | May 12, 2025 |
| May 8, 2025 | Alan S. Roemer director | AGrant or award Stock Option (right to buy)derivative | +63,150 | $0.00 | $0 | 63,150 | May 12, 2025 |
| May 8, 2025 | Luba Greenwood director | AGrant or award Stock Option (right to buy)derivative | +63,150 | $0.00 | $0 | 63,150 | May 12, 2025 |
| May 8, 2025 | Emily Fairbairn director | AGrant or award Stock Option (right to buy)derivative | +63,150 | $0.00 | $0 | 63,150 | May 12, 2025 |
| May 8, 2025 | Jeremy R. Graff director | AGrant or award Stock Option (right to buy)derivative | +63,150 | $0.00 | $0 | 63,150 | May 12, 2025 |
| Apr 27, 2025 | Corinne Epperly director | DDisposition to issuer Series B Warrants (right to buy)derivative | -81,967 | - | - | 0 | May 7, 2025 |
| Apr 30, 2025 | Kate Rochlin Chief Operating Officer | MOption exercise Common Stock | +12,295 | $0.18 | $2,267 | 55,169 | May 7, 2025 |
| Apr 27, 2025 | Jeremy R. Graff director | DDisposition to issuer Series B Warrants (right to buy)derivative | -2,049 | - | - | 0 | May 7, 2025 |
| Apr 30, 2025 | Patrick McCall CHIEF FINANCIAL OFFICER | MOption exercise Common Stock | +15,000 | $0.18 | $2,766 | 67,071 | May 7, 2025 |
| Apr 27, 2025 | William Tai-Wei Ho PRESIDENT AND CEO | DDisposition to issuer Series B Warrants (right to buy)derivative | -81,967 | - | - | 0 | May 7, 2025 |
| Apr 30, 2025 | Alan S. Roemer director | MOption exercise Common Stock | +102,459 | $0.18 | $19k | 387,489 | May 7, 2025 |
| Apr 30, 2025 | Peter C. Brandt director | MOption exercise Common Stock | +81,967 | $0.18 | $15k | 599,571 | May 7, 2025 |
| Apr 27, 2025 | Lawrence Lamb EVP and CSO | DDisposition to issuer Series B Warrants (right to buy)derivative | -1,639 | - | - | 0 | May 7, 2025 |
| Apr 30, 2025 | Peter C. Brandt director | MOption exercise Common Stock | +81,967 | $0.18 | $15k | 681,538 | May 7, 2025 |
| Apr 27, 2025 | William Tai-Wei Ho PRESIDENT AND CEO | AGrant or award Series B Warrants (right to buy)derivative | +81,967 | - | - | 81,967 | May 7, 2025 |
| Apr 27, 2025 | Patrick McCall CHIEF FINANCIAL OFFICER | DDisposition to issuer Series A Warrants (right to buy)derivative | -15,000 | - | - | 5,492 | May 7, 2025 |
| Apr 30, 2025 | Alan S. Roemer director | MOption exercise Common Stock | +11,000 | $0.18 | $2,028 | 398,489 | May 7, 2025 |
| Apr 27, 2025 | Jeremy R. Graff director | AGrant or award Series B Warrants (right to buy)derivative | +2,049 | - | - | 2,049 | May 7, 2025 |
| Apr 27, 2025 | Kate Rochlin Chief Operating Officer | DDisposition to issuer Series A Warrants (right to buy)derivative | -12,295 | - | - | 0 | May 7, 2025 |
| Apr 27, 2025 | Corinne Epperly director | AGrant or award Series B Warrants (right to buy)derivative | +81,967 | - | - | 81,967 | May 7, 2025 |
| Apr 27, 2025 | Lawrence Lamb EVP and CSO | AGrant or award Series B Warrants (right to buy)derivative | +1,639 | - | - | 1,639 | May 7, 2025 |
| May 1, 2025 | William Tai-Wei Ho PRESIDENT AND CEO | DDisposition to issuer Series A Warrants (right to buy)derivative | -81,967 | - | - | 0 | May 7, 2025 |
| Apr 27, 2025 | Alan S. Roemer director | DDisposition to issuer Series A Warrants (right to buy)derivative | -102,459 | - | - | 0 | May 7, 2025 |
| Apr 27, 2025 | Patrick McCall CHIEF FINANCIAL OFFICER | AGrant or award Series A Warrants (right to buy)derivative | +15,000 | - | - | 15,000 | May 7, 2025 |
| Apr 27, 2025 | Kate Rochlin Chief Operating Officer | AGrant or award Series A Warrants (right to buy)derivative | +12,295 | - | - | 12,295 | May 7, 2025 |
| Apr 27, 2025 | Alan S. Roemer director | AGrant or award Series A Warrants (right to buy)derivative | +102,459 | - | - | 102,459 | May 7, 2025 |
| Apr 27, 2025 | Peter C. Brandt director | DDisposition to issuer Series A Warrants (right to buy)derivative | -81,967 | - | - | 0 | May 7, 2025 |
| Apr 30, 2025 | Kate Rochlin Chief Operating Officer | MOption exercise Series A Warrants (right to buy)derivative | -12,295 | $0.00 | $0 | 0 | May 7, 2025 |
| Apr 30, 2025 | Patrick McCall CHIEF FINANCIAL OFFICER | MOption exercise Series A Warrants (right to buy)derivative | -15,000 | $0.00 | $0 | 0 | May 7, 2025 |
| May 1, 2025 | William Tai-Wei Ho PRESIDENT AND CEO | AGrant or award Pre-Funded Warrant (right to buy)derivative | +81,967 | $0.18 | $15k | 81,967 | May 7, 2025 |
| Apr 27, 2025 | Peter C. Brandt director | AGrant or award Series A Warrants (right to buy)derivative | +81,967 | - | - | 81,967 | May 7, 2025 |
| Apr 30, 2025 | Alan S. Roemer director | MOption exercise Series A Warrants (right to buy)derivative | -102,459 | $0.00 | $0 | 0 | May 7, 2025 |
| Apr 27, 2025 | Kate Rochlin Chief Operating Officer | DDisposition to issuer Series B Warrants (right to buy)derivative | -12,295 | - | - | 0 | May 7, 2025 |
| Apr 27, 2025 | Patrick McCall CHIEF FINANCIAL OFFICER | DDisposition to issuer Series B Warrants (right to buy)derivative | -20,492 | - | - | 0 | May 7, 2025 |
| Apr 27, 2025 | Kate Rochlin Chief Operating Officer | AGrant or award Series B Warrants (right to buy)derivative | +12,295 | - | - | 12,295 | May 7, 2025 |
| Apr 30, 2025 | Peter C. Brandt director | MOption exercise Series A Warrants (right to buy)derivative | -81,967 | $0.00 | $0 | 0 | May 7, 2025 |
| Apr 27, 2025 | Alan S. Roemer director | DDisposition to issuer Series B Warrants (right to buy)derivative | -102,459 | - | - | 0 | May 7, 2025 |
| Apr 27, 2025 | Patrick McCall CHIEF FINANCIAL OFFICER | AGrant or award Series B Warrants (right to buy)derivative | +20,492 | - | - | 20,492 | May 7, 2025 |
| Apr 27, 2025 | Peter C. Brandt director | DDisposition to issuer Series B Warrants (right to buy)derivative | -81,967 | - | - | 0 | May 7, 2025 |
| Apr 27, 2025 | Alan S. Roemer director | AGrant or award Series B Warrants (right to buy)derivative | +11,000 | - | - | 11,000 | May 7, 2025 |
| May 2, 2025 | Aaron G.L. Fletcher owner | POpen-market purchase Pre-Funded Warrantsderivativeindirect: By Bios Clinical Opportunity Fund, LP | +1,148,482 | - | - | 2,431,763 | May 7, 2025 |
| May 2, 2025 | Leslie W. Kreis owner | POpen-market purchase Pre-Funded Warrantsderivativeindirect: By Bios Clinical Opportunity Fund, LP | +1,148,482 | - | - | 2,431,763 | May 7, 2025 |
| Apr 30, 2025 | Alan S. Roemer director | MOption exercise Series B Warrants (right to buy)derivative | -11,000 | $0.00 | $0 | 0 | May 7, 2025 |
| Apr 27, 2025 | Peter C. Brandt director | AGrant or award Series B Warrants (right to buy)derivative | +81,967 | - | - | 81,967 | May 7, 2025 |
| Apr 27, 2025 | Alan S. Roemer director | AGrant or award Series B Warrants (right to buy)derivative | +91,459 | - | - | 91,459 | May 7, 2025 |
| Apr 30, 2025 | Peter C. Brandt director | MOption exercise Series B Warrants (right to buy)derivative | -81,967 | $0.00 | $0 | 0 | May 7, 2025 |
| May 2, 2025 | Aaron G.L. Fletcher owner | JOther Series A Warrantderivativeindirect: By Bios Clinical Opportunity Fund, LP | -574,241 | - | - | 0 | May 7, 2025 |
| May 2, 2025 | Leslie W. Kreis owner | JOther Series A Warrantderivativeindirect: By Bios Clinical Opportunity Fund, LP | -574,241 | - | - | 0 | May 7, 2025 |
| May 2, 2025 | Leslie W. Kreis owner | JOther Series B Warrantderivativeindirect: By Bios Clinical Opportunity Fund, LP | -574,241 | - | - | 0 | May 7, 2025 |
| May 2, 2025 | Aaron G.L. Fletcher owner | JOther Series B Warrantderivativeindirect: By Bios Clinical Opportunity Fund, LP | -574,241 | - | - | 0 | May 7, 2025 |
| Feb 5, 2025 | Kate Rochlin Chief Operating Officer | AGrant or award Employee Stock Option (right to buy)derivative | +338,950 | $0.00 | $0 | 338,950 | Feb 7, 2025 |
| Feb 5, 2025 | Patrick McCall CHIEF FINANCIAL OFFICER | AGrant or award Employee Stock Option (right to buy)derivative | +343,000 | $0.00 | $0 | 343,000 | Feb 7, 2025 |
| Feb 5, 2025 | Lawrence Lamb EVP and CSO | AGrant or award Employee Stock Option (right to buy)derivative | +306,750 | $0.00 | $0 | 306,750 | Feb 7, 2025 |
| Feb 5, 2025 | William Tai-Wei Ho PRESIDENT AND CEO | AGrant or award Employee Stock Option (right to buy)derivative | +912,450 | $0.00 | $0 | 912,450 | Feb 7, 2025 |
| Dec 19, 2024 | Jeremy R. Graff director | AGrant or award Stock Option (right to buy)derivative | +47,697 | $0.00 | $0 | 47,697 | Dec 23, 2024 |
| Dec 19, 2024 | Travis Whitfill director | AGrant or award Stock Option (right to buy)derivative | +42,676 | $0.00 | $0 | 42,676 | Dec 23, 2024 |
| Dec 19, 2024 | Alan S. Roemer director | AGrant or award Stock Option (right to buy)derivative | +93,242 | $0.00 | $0 | 93,242 | Dec 23, 2024 |
| Dec 19, 2024 | Patrick McCall CHIEF FINANCIAL OFFICER | AGrant or award Employee Stock Option (right to buy)derivative | +290,085 | $0.00 | $0 | 290,085 | Dec 23, 2024 |
| Dec 19, 2024 | Lawrence Lamb EVP and CSO | AGrant or award Employee Stock Option (right to buy)derivative | +286,899 | $0.00 | $0 | 286,899 | Dec 23, 2024 |
| Dec 19, 2024 | Kate Rochlin Chief Operating Officer | AGrant or award Employee Stock Option (right to buy)derivative | +302,839 | $0.00 | $0 | 302,839 | Dec 23, 2024 |
| Dec 19, 2024 | William Tai-Wei Ho PRESIDENT AND CEO | AGrant or award Employee Stock Option (right to buy)derivative | +1,188,282 | $0.00 | $0 | 1,188,282 | Dec 23, 2024 |
| Dec 19, 2024 | Luba Greenwood director | AGrant or award Stock Option (right to buy)derivative | +39,449 | $0.00 | $0 | 39,449 | Dec 23, 2024 |
| Dec 19, 2024 | Emily Fairbairn director | AGrant or award Stock Option (right to buy)derivative | +31,559 | $0.00 | $0 | 31,559 | Dec 23, 2024 |
| Dec 19, 2024 | Corinne Epperly director | AGrant or award Stock Option (right to buy)derivative | +37,655 | $0.00 | $0 | 37,655 | Dec 23, 2024 |
| Dec 19, 2024 | Peter C. Brandt director | AGrant or award Stock Option (right to buy)derivative | +49,490 | $0.00 | $0 | 49,490 | Dec 23, 2024 |
| Oct 4, 2024 | Aaron G.L. Fletcher owner | POpen-market purchase Pre-Funded Warrantsderivativeindirect: By Bios Clinical Opportunity Fund, LP | +709,040 | - | - | 1,283,281 | Oct 11, 2024 |
| Oct 4, 2024 | Leslie W. Kreis owner | POpen-market purchase Pre-Funded Warrantsderivativeindirect: By Bios Clinical Opportunity Fund, LP | +709,040 | - | - | 1,283,281 | Oct 11, 2024 |
| Oct 4, 2024 | Aaron G.L. Fletcher owner | POpen-market purchase Series C Warrantderivativeindirect: By Bios Clinical Opportunity Fund, LP | +709,040 | - | - | 709,040 | Oct 11, 2024 |
| Oct 4, 2024 | Leslie W. Kreis owner | POpen-market purchase Series C Warrantderivativeindirect: By Bios Clinical Opportunity Fund, LP | +709,040 | - | - | 709,040 | Oct 11, 2024 |
| Oct 4, 2024 | Aaron G.L. Fletcher owner | DDisposition to issuer Series A Warrantderivativeindirect: By Bios Clinical Opportunity Fund, LP | +574,241 | - | - | 0 | Oct 11, 2024 |
| Oct 4, 2024 | Leslie W. Kreis owner | DDisposition to issuer Series A Warrantderivativeindirect: By Bios Clinical Opportunity Fund, LP | +574,241 | - | - | 0 | Oct 11, 2024 |
| Oct 4, 2024 | Aaron G.L. Fletcher owner | AGrant or award Series A Warrantderivativeindirect: By Bios Clinical Opportunity Fund, LP | +574,241 | - | - | 574,241 | Oct 11, 2024 |
| Oct 4, 2024 | Leslie W. Kreis owner | AGrant or award Series A Warrantderivativeindirect: By Bios Clinical Opportunity Fund, LP | +574,241 | - | - | 574,241 | Oct 11, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Peter C. Brandtdirector
- Corinne Epperlydirector
- Emily Fairbairndirector
- Aaron G.L. Fletcherowner, director
- Jeremy R. Graffdirector, officer
- Luba Greenwooddirector
- William Tai-Wei HoPRESIDENT AND CEO
- Leslie W. Kreisowner, director
- Lawrence LambEVP and CSO
- Patrick McCallCHIEF FINANCIAL OFFICER
- Kate RochlinChief Operating Officer
- Alan S. Roemerdirector
- Travis Whitfilldirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.